Last 29 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.27 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.56 | 4.58 | 1.31 | 1.48 | 0.39 | 0.82 | 1.09 | 2.65 | 6.49 | 3.69 | 3.59 | 3.19 | 2.88 |
| — | +458.8% | +20.8% | -44.1% | -94.0% | -77.8% | -69.8% | -16.8% | +125.1% | -13.8% | +27.7% | -17.8% | -50.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -77.1% | -11.1% | -10.3% | -9.3% | -37.3% | -18.0% | -23.0% | -22.0% | -19.3% | -16.8% | -12.0% | -12.6% | -10.6% |
| — | +38.3% | +55.2% | +57.5% | -93.3% | -6.9% | -91.5% | -74.7% | -82.7% | -55.3% | -16.0% | -8.8% | -14.4% | |
| ROA | -62.8% | -10.2% | -9.6% | -8.0% | -30.5% | -15.6% | -19.6% | -18.5% | -16.6% | -14.9% | -10.8% | -11.4% | -9.6% |
| — | +34.7% | +50.7% | +56.7% | -84.5% | -4.8% | -81.4% | -63.0% | -71.5% | -51.6% | -15.1% | -7.3% | -12.0% | |
| ROIC | -155.7% | -12.0% | -11.9% | -19.8% | -93.5% | -21.1% | -25.9% | -24.6% | -21.4% | -17.9% | -12.5% | -11.9% | -9.5% |
| — | +43.2% | +54.2% | +19.3% | -336.4% | -17.7% | -107.6% | -107.0% | -124.9% | -78.0% | -30.8% | -16.8% | -7.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 21.6% YoY to 12.04x, strengthening the short-term liquidity position. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 |
| — | -68.1% | -63.3% | -55.3% | -49.6% | +24.1% | +30.9% | +25.0% | +28.1% | +3.9% | -1.5% | -24.5% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.87 | 12.04 | 13.25 | 21.11 | 4.87 | 9.90 | 8.14 | 7.01 | 7.41 | 8.57 | 13.46 | 10.86 | 17.77 |
| — | +21.6% | +62.8% | +201.2% | -34.3% | +15.6% | -39.5% | -35.4% | -58.3% | -40.0% | -15.7% | -23.6% | -11.7% | |
| Quick Ratio | 4.87 | 12.04 | 13.25 | 21.11 | 4.87 | 9.90 | 8.14 | 7.01 | 7.41 | 8.57 | 13.46 | 10.86 | 17.77 |
| — | +21.6% | +62.8% | +201.2% | -34.3% | +15.6% | -39.5% | -35.4% | -58.3% | -40.0% | -15.7% | -23.6% | -11.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonRAPT Therapeutics, Inc.'s current P/E is -2.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking RAPT Therapeutics, Inc.'s business trajectory between earnings reports.